07 May 2020
Visiongain has launched a new pharma report Erectile Dysfunction Market Report 2020-2030: Forecasts by Type (Pharmaceuticals (Viagra (Sildenafil Citrate), Cialis (Tadalafil), Levitra/Staxyn (Vardenafil), Stendra/Spedra (Avanafil), Zydena (Udenafil), Vitaros (Alprostadil)) and Nutraceuticals (Dietary Supplements (DHEA, VIgRX Plus, IDIProst, Prelox, Tradamix TX 1000, Others); HerbalNatural, (Horny Goat Weed, Ginko, Red Ginseng, Yohimbine, Panax Ginseng, Cappra, Pyongenol, Lepidamax, REVACTIN, Others)), Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). PLUS Profiles of Leading Companies) and Regional and Leading National Market Analysis.
The global market for erectile dysfunction is anticipated to surpass US$2.5 billion in 2020 and is further projected to surpass US$ 3.5 billion in 2030 while growing at a CAGR of 2.7% over the forecast period from 2020 to 2030.
The growing awareness of erectile dysfunction is the main growth driver for the global market, as people who would otherwise be hesitant in purchasing ED products are now buying them without any restrictions. An increase in marketing efforts by drug manufacturers to sell their products across various geographies has further propelled the growth of global erectile dysfunction medications market in the past few years. Growing awareness of drugs over the forecast period will likely remain a key driver for the global market for erectile dysfunction drugs.
Increasing competition among manufacturers of generic erectile dysfunction drugs as well as the rise in availability of counterfeit erectile dysfunction drugs is likely to remain the key restraint of the global erectile dysfunction drugs market during the forecast period. Due to the patent expiry of blockbuster drugs, many generic variants have been launched in the market, with competitive pricing among these manufactures. This is expected to cause cannibalization of the erectile dysfunction drugs market for branded drugs in the coming years, with consumers often preferring lower-priced generic variants of erectile dysfunction drugs over expensive blockbuster varieties.
The Visiongain analyst commented: "The global erectile dysfunction is in a transition phase as the majority of the consumers are shifting from traditional pharmaceuticals to herbal-based products pertaining to lesser side effects and positive perception of natural products amongst the society. Visiongain understands this market to be dynamic, with a large number of players to enter the market."
North America dominated the global market with over 40% market share which is anticipated to reach maintain its leadership over the forecast period, the North American market is projected to hold a 39.5% market share by 2030.
APAC is the second-largest market for erectile dysfunction market globally. Japan, ASEAN, China, and India are the major revenue contributors to the APAC ED treatment market. These four countries together accounted for a share of over 85% of the ED treatment market in APAC.
The market in the APAC region is growing at a steady pace, and this trend is expected to continue during the forecast period due to the high prevalence of ED in developing countries. Also, the healthcare industry in the region is undergoing a rapid transformation with favorable support from various government organizations and vendors to increase the uptake of therapeutics to treat various diseases.
The country-specific epidemiological surveys in the APAC region indicated that the prevalence of ED is increasing. In several APAC countries, awareness about ED drugs is rising steadily. The launch of many awareness campaigns, an increase in disposable income, and the availability of low-cost treatment are some of the factors that are fuelling the growth of the ED treatment market in this region.
This report will evaluate the market factors that act to drive and restrain the erectile dysfunction market, providing forecasts for the global market, regional markets, and associated submarkets. With the analysis of key market trends, this report will provide a detailed overview of the market.
Some of the prominent companies profiled in this report include Bayer AG, Eli Lilly and Company, Ferring B.V., GSK, Pfizer Inc., Teva Pharmaceuticals, Vivus Inc., Dong Pharmaceuticals, SK Chemicals Co Ltd., and Apricus Biosciences Inc. among other players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
26 May 2022
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.